Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Linda Pearson who wrote (329)	2/1/1999 4:17:00 PM
From: LLCF	Read Replies (1) \| Respond to of 613

<Maybe you can provide the article for those of us who are curious why you are slamming the stock.> Don't shoot the mailman as they say: cbs.marketwatch.com Lots of stocks have gotten hit lately after positive FDA panel votes and approvals... even ones much more positive than this. That said, the stock was up on the day. DAK

To: Linda Pearson who wrote (329)	2/1/1999 4:53:00 PM
From: RCMac	Respond to of 613

>>I didn't find any article on Scios in the Wall Street Journal, let alone one that isn't upbeat. Maybe you can provide the article for those of us who are curious why you are slamming the stock.<< The article on SCIO, on page B5 of my WSJ, notes the FDA panel recommendation of approval of Natrecor, but goes on: " . . . but some analysts consider its sales prospects limited." . . . "Several analysts said Natrecor will face tough sledding in a market already filled with treatment options." Not exactly upbeat. Especially in light of the observation about CEPH's and other biotech's post-approval declines that TexasDude was responding to, his comment hardly seems like "slamming" the stock. -- RCM

To: Linda Pearson who wrote (329)	2/1/1999 5:05:00 PM
From: WWS	Read Replies (2) \| Respond to of 613

Linda, here is the URL to the Scios news feed in WSJ-online (subscription necessary). And while you're over there, why not stop to inquire about taking some basic driving lessons on this here newfangled "information super highway"? interactive.wsj.com

To: Linda Pearson who wrote (329)	2/1/1999 5:08:00 PM
From: Arthur Radley	Respond to of 613

Linda, I'm sorry that you thought I was "slamming" Scios, if you follow many of my post you will find that I'm a big supporter of the biotech industry. For my pocketbook and the good of mankind/womankind, I hope every biotech has great success in bringing new drugs to the market. The observation I made about SCIO was based on the article which has been referenced for you and which I clearly stated in my earlier post and when it states the FDA panel... "narrowly voted to recommend Natrecor as a short-term intravenous treatment" and further states..."several analysts said Natrecor will face tough sledding in a market already filled with treatment options", I'm still inclined to say that this information isn't "upbeat".(:>)